tumors may benefit more than HER2+/HR+ tumors from dual HER2 blockade, according to 5-year results from the phase III ALTTO trial. The Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation study, or ALTTO, is an international phase III clinical trial of two targeted. Background: Pre-specified 5-year analyses of the phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) Trial.
| Author: | Kagul Samukinos |
| Country: | Australia |
| Language: | English (Spanish) |
| Genre: | Art |
| Published (Last): | 17 October 2006 |
| Pages: | 425 |
| PDF File Size: | 10.57 Mb |
| ePub File Size: | 17.2 Mb |
| ISBN: | 598-8-51561-118-5 |
| Downloads: | 90143 |
| Price: | Free* [*Free Regsitration Required] |
| Uploader: | Grozuru |
Equivocal local results may be submitted for a final determination by the central laboratory.
Breast Cancer Res Treat Presented June 1, You CAN’T join if Oxford University Press is a department of the University of Oxford. Study treatment wltto start no more than 14 days after randomization and must be concurrent with taxanes. The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab, or their combination in HER2-positive breast cancer.
Oral, injectable, or implant hormonal contraceptives are not indicated in this patient population ; Concomitant use of CYP3A4 inhibitors or inducers. Perez did find something positive in the results, as she noted to the media that the disease-free events that occurred at 4. Patients with a prior malignancy diagnosed greater than 10 years in the past who have been curatively treated with surgery ONLY, WITHOUT radiation therapy or systemic therapy chemotherapy or endocrine are eligible for the study.
Expert Point of View: Unresolved or unstable serious adverse events from prior adjuvant chemotherapy or radiotherapy; Malabsorption syndrome, any disease significantly affecting gastrointestinal function,or resection of the stomach or small bowel, or persons unable to swallow oral medication.
IBCSG /BIG (ALTTO)
The following dosing schemes were used:. In this study, the distant recurrence events rate was higher in the RNI patients. We congratulate Gingras et al. Treatment Controversy Eva M.
After surgery and a standard treatment with chemotherapy, patients enrolled in ALTTO were randomly assigned to receive one of these four treatments for a period of 1 year: Regional nodal irradiation after breast-conserving surgery for early HER2-positive breast cancer: For full disclosures of all altho study authors, visit abstracts.
ALTTO recruited 8, patients between and It works inside the cells to slow or stop the processes that cause tumour growth and disease progression.
Randomisation must be performed no longer than 8 weeks from definitive surgery. Serious cardiac illness or medical conditions including but not confined to: Perez reported no potential conflicts of interest.
Patients will be followed for at least 10 years after enrolment; as of 1 Julyall patients had been followed for at least 5 years.
IBCSG 36-07/BIG 2-06 (ALTTO)
Email alerts New issue alert. As RNI clearly contributes to improving distant metastasis—free survival DMFS 23it is alttto why these rules, widely accepted in all BC patients, would be unsuitable for the more aggressive HER2-positive disease.
Given all of these points, we have doubts atlto the conclusions of the ALTTO-retrospective findings for obvious reasons: If the patient is node-negative: Piccart-Gebhart noted in her presentation. Receive exclusive offers and updates from Oxford Academic. Presented December 11, Correlative analyses of tissue samples is underway, and this may help to identify whether subsets of patients did benefit from the adjuvant combination. Lapatinib is another drug developed to treat HER2-positive breast cancer.
When the study was troal, it was thought that using both drugs combined or in sequence might work better than giving either drug alone. Published by Oxford University Press.